Overview

Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC

Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
It is a phase III trial to explore the efficacy and safety of metronomic chemotherapy with Capecitabine versus intermittent Capecitabine as maintenance therapy following first-line Capecitabine plus Docetaxel chemotherapy in treatment of HER2-negative metastatic breast cancer(mBC).
Phase:
Phase 3
Details
Lead Sponsor:
Binghe Xu
Collaborator:
Hoffmann-La Roche
Treatments:
Capecitabine
Docetaxel